Page 7 - Otonomy Inc News Today

GuruFocus Article or News written by GuruFocusNews and the topic is about:

/PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative...

/PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative...

Results published in Otology & Neurotology, a leading journal in fieldOTO-313 was well-tolerated and demonstrated a statistically significant higher...

/PRNewswire/ -- ALK (ALKB:DC / OMX:ALK B / AKABY / AKBLF), a global, research-driven pharmaceutical company that focuses on the diagnosis and treatment of...

AGTC Appoints Regulatory Expert, Janet C. Rae, RAC, as SVP of Global Regulatory and Quality GAINESVILLE, Fla. and CAMBRIDGE, Mass., May 26, 2021 (GLOBE...

AGTC Expands Leadership Team with Appointment of Key Regulatory Leader - read this article along with other careers information, tips and advice on BioSpace

Otonomy: Q1 Earnings Snapshot Last Updated May 11, 2021 at 5:28 pm EDT SAN DIEGO (AP) _ Otonomy Inc. (OTIC) on Tuesday reported a loss of $12.2 million in its first quarter. The San Diego-based company said it had a loss of 23 cents per share. The biotechnology company posted revenue of $90,000 in the period. In the final minutes of trading on Tuesday, the company’s shares hit $2.08. A year ago, they were trading at $2.45. _____ This story was generated by Automated Insights (http://automated...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Otonomy Reports First Quarter 2021 Financial Results and Provides Corporate Update Otonomy, Inc.May 11, 2021 GMT OTO-313 Phase 2 trial in tinnitus initiated with results expected in mid-2022 OTO-413 Phase 1/2 trial expansion in hearing loss expected to start in second quarter of 2021 with results anticipated in mid-2022 OTO-825 IND-enabling activities underway with preclinical proof-of-concept data to...

Share: OTO-313 Phase 2 trial in tinnitus initiated with results expected in mid-2022 OTO-413 Phase 1/2 trial expansion in hearing loss expected to start in second quarter of 2021 with results anticipated in mid-2022 OTO-825 IND-enabling activities underway with preclinical proof-of-concept data to be presented at ASGCT meeting; update on program to be provided in mid-2021 Recent financing extends cash runway into second half of 2023 Conference call and webcast today at 4:30 p.m. ET SAN DIEGO, M...